What's Actually In That · Part 4 · Supplement Quality & GMP
In October 2005, I sat in a room at a Crayhon Research Nutrient Expo and listened to a talk on supplement quality control that I have never forgotten. The speaker — a quality director from one of the major US supplement manufacturers — explained something that has shaped how I think about supplements ever since: in most commercial supplement manufacturing, the dose in each capsule is not determined by the therapeutic dose in the research. It is determined by the flow rate of the encapsulating machine.
The conference was organised by Robert Crayhon — one of the most forensically rigorous minds in functional nutrition at the time. The programme included Rick Liva, ND, RPh on quality control in the supplements industry; Nigel Plummer, PhD, on probiotic quality and clinical efficacy; Michael Holick, MD, PhD on vitamin D therapy; and Andreanna Vaughn, RN, presenting on toxic metal elimination from her work with Dietrich Klinghardt, MD. The conversations happening in that room in 2005 were twenty years ahead of mainstream clinical practice. Most of them still are.
I am writing about this now because the supplement quality problem that was described in that room in October 2005 is, in all its essential features, identical to the supplement quality problem that exists in 2026. The shiny new products have changed. The underlying structural issues have not. Plus ça change.
This is the detail that stays with you. Commercial supplement encapsulation relies on machines that fill hundreds of thousands of capsules per hour. For the machines to run efficiently — without jamming, without irregular fill weights, without downtime — the powdered ingredients must flow consistently through the hopper and into each capsule at a predictable rate.
Particle size matters. Moisture content matters. Electrostatic charge matters. The presence of certain excipients and flow agents matters. And — critically — the form of the active ingredient matters. Some forms of a nutrient flow well. Others clump, bridge, or stick. When a manufacturer is choosing between two forms of, say, magnesium — one that flows smoothly at the required rate and one that clumps at high throughput — the manufacturing decision and the clinical decision point in different directions.
Magnesium oxide flows beautifully. It is cheap, it is stable, it is light, and it fills capsules at consistent weights without interrupting the production line. Magnesium glycinate — the chelated form with significantly superior absorption — is hygroscopic (absorbs moisture), tends to clump, and is considerably more expensive per gram of elemental magnesium. From a manufacturing economics standpoint, the decision is straightforward. From a clinical standpoint, the decision produces a product that is essentially inert for raising cellular magnesium levels.
The patient who bought the magnesium supplement because they read it would help their sleep and muscle tension, tried it for two months and noticed nothing, and concluded that magnesium supplements don't work — was not wrong about the magnesium. They were wrong about whether what was in the capsule was delivering the magnesium.
I have the conference programme from October 2005 on my desk as I write this. Rick Liva, ND, RPh speaking on "Quality Control in the Supplements Industry: The Need for a Higher Standard for Clinical Results and Safety of Natural Products." That was the first session on the Thursday morning. Twenty years ago.
The conversation in that room was sophisticated, specific, and clinically grounded. It covered raw material testing, GMP compliance, excipient safety, label accuracy, and the gap between research doses and commercial doses. The practitioners in the room left with a more nuanced understanding of supplement quality than most practitioners have today.
And yet here we are in 2026 having the same conversation. The products are different. The mechanisms of quality compromise are identical. The consumer assumption — that if it's on a reputable-looking shelf in a health food shop or on a well-designed website, the label is accurate and the dose is therapeutic — is as widespread and as wrong as it was in 2005.
There is something both depressing and clarifying about this. The fundamentals do not change. The people chasing the newest supplement trend, the latest biohacking compound, the most recently hyped botanical — they are frequently doing so with products that have the same fundamental quality problems as the supplements of twenty years ago, while overlooking the basics that have been clinically validated for decades. Vitamin D. Magnesium. B12 in the correct form. Zinc as bisglycinate. Omega-3 at a therapeutic EPA dose. These are not exciting. They are evidence-based, often deficient, and almost never formulated correctly in the cheap end of the market.
The shiny new supplement often has the same quality problems as the boring old one. The boring old nutrients, formulated correctly and at therapeutic doses, frequently outperform the novel compound marketed with impressive-sounding research that the product doesn't actually replicate.
GMP (Good Manufacturing Practice) certification is the minimum quality standard for supplement manufacturing in the UK and US. UK supplements must comply with EU/UK food law GMP requirements; in the US, the FDA enforces 21 CFR Part 111, the dietary supplement GMP regulations. GMP compliance means a facility has documented quality control procedures, staff training, equipment maintenance records, and complaint handling systems.
What GMP does not guarantee:
It does not guarantee the ingredient form is bioavailable. A GMP-certified facility can produce magnesium oxide tablets with perfect consistency and full regulatory compliance. The product is GMP-compliant and clinically inadequate simultaneously.
It does not guarantee the dose is therapeutic. The GMP regulation governs manufacturing consistency — that each tablet contains what the label says, within permitted tolerances. It does not regulate whether what the label says is clinically meaningful.
It does not guarantee raw material purity beyond minimum standards. GMP requires testing but does not specify the sensitivity of the testing or the frequency. A manufacturer meeting minimum GMP requirements may test a single batch of a raw material per year. A high-quality manufacturer tests every batch.
It does not guarantee identity of botanical ingredients. Adulteration of botanical raw materials — substituting cheaper related species for the claimed ingredient — is one of the most common forms of supplement fraud and is not reliably caught by standard GMP testing. DNA fingerprinting is required to confirm botanical identity, and most GMP-compliant manufacturers do not routinely conduct it.
There is a separate quality problem that practitioners are often reluctant to acknowledge. Practitioner-grade supplement brands — the companies that sell only through licensed practitioners and maintain higher GMP standards — are genuinely better than most retail products. The raw material sourcing is more rigorous, the testing is more frequent, and the ingredient forms are generally more bioavailable.
But even within practitioner brands, the dose on the label is often the label dose rather than the therapeutic dose. A practitioner who recommends a supplement at the labelled dose, because that is what the label suggests and because the product insert follows the same convention, may be delivering a fraction of the dose used in the studies that justified the recommendation. The practitioner knows the brand is high quality. The dose question is a separate one that is not always asked.
This is not discussed systematically in functional medicine training. The assumption is that practitioner brands are better and therefore appropriate — which is partly true. The dose question requires a separate layer of clinical reasoning that goes: what dose was used in the research showing this effect? Is the product's suggested dose within that range? If not, is there a clinical rationale for the lower dose, or is it a commercial convenience that happens to be presented as clinical guidance?
Robert Crayhon died in 2010 — too young, at 45. He was one of the most rigorous and intellectually honest figures in clinical nutrition of his generation. The conference programme on my desk is a document from a time when a room full of practitioners were being given the kind of specific, commercially uncomfortable, clinically useful information about supplement quality that most practitioners still haven't received.
The fact that this conversation is still necessary in 2026 is not an indictment of the supplement industry alone. It is an indictment of a professional culture that has not made supplement quality literacy a standard part of clinical training, that has allowed the marketing language of quality ("GMP certified," "third-party tested," "practitioner grade") to substitute for the harder questions about ingredient form, dose adequacy, raw material provenance, and the gap between what the label says and what the research requires.
The basics are solid gold. The right form, at the right dose, in the right person, targeted by test results rather than marketing copy. Twenty years ago. Today. The conversation is the same. The good news is that the answer is the same too.
The DH Clinical Concierge can audit your current supplement protocol — ingredient forms, doses, likely gaps between label and therapeutic dose, and what your test results actually suggest you need.
Supplement Audit →